Table A.5.
Clinical and demographic characteristics of participants who did not complete study follow-up, by number of days of follow-up in the trial
| NCF within the first 331 days (n = 352) | NCF between 332 and 662 days (n = 167) | NCF between 663 and 993 days (n = 322) | |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Person-month | 1214 | 2892 | 9538 |
| Regimen* | |||
| 3HP-DOT | 168 (47.7) | 78 (46.7) | 145 (45.7) |
| 9H-SAT | 184 (52.3) | 89 (53.3) | 175 (54.4) |
| Age, years, median [IQR] | 35 [26–45] | 35 [26–45] | 36 [26–45] |
| Male sex | 228 (64.8) | 112 (67.1) | 170 (52.8) |
| Race | |||
| White | 186 (52.8) | 96 (57.5) | 185 (57.5) |
| African American | 95 (27.0) | 42 (25.2) | 73 (22.7) |
| Asian | 33 (9.4) | 14 (8.4) | 19 (5.9) |
| Other† | 38 (10.8) | 15 (9.0) | 45 (14.0) |
| Ethnicity | |||
| Hispanic | 146 (41.5) | 80 (47.9) | 147 (45.7) |
| Non-Hispanic | 180 (51.1) | 78 (46.7) | 140 (43.5) |
| Spain | 9 (2.6) | 4 (2.4) | 13 (4.0) |
| Brazil | 17 (4.8) | 5 (3.0) | 22 (6.8) |
| HIV status | |||
| Positive | 11 (3.1) | 4 (2.34) | 10 (3.1) |
| Negative | 167 (47.4) | 87 (52.1) | 179 (55.6) |
| Unknown | 174 (49.4) | 76 (45.5) | 133 (41.3) |
| Country of birth | |||
| US | 114 (32.4) | 55 (32.9) | 121 (37.6) |
| Non-US | 238 (67.6) | 112 (67.1) | 201 (62.4) |
| Body mass index, median [IQR] | 27 [24–30] | 27 [24–31] | 27 [24–31] |
| Education | |||
| ⩽8th grade | 81 (23.0) | 37 (22.2) | 70 (21.7) |
| 9th grade, some college | 216 (61.4) | 110 (65.9) | 211 (65.5) |
| College or higher | 55 (15.6) | 20 (12.0) | 41 (12.7) |
| History of incarceration | 33 (9.4) | 17 (10.2) | 24 (7.5) |
| Unemployed | 43 (12.2) | 24 (14.4) | 41 (12.7) |
| Homeless | 42 (11.9) | 28 (16.8) | 29 (9.0) |
| Alcohol consumption | |||
| No | 147 (41.8) | 60 (35.9) | 160 (49.7) |
| Use | 169 (48.0) | 83 (49.7) | 144 (44.7) |
| Abuse | 36 (10.2) | 24 (14.4) | 18 (5.6) |
| Injection drug use | 22 (6.3) | 5 (3.0) | 19 (5.9) |
| Current smoker | 137 (38.9) | 76 (45.5) | 103 (32.0) |
*
3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily selfadministered INH (maximum dose, 300 mg).
†
Includes North American Indian and other participants in the United States and Canada.
NCF=non-completion of follow-up; H, INH=isoniazid; P, RPT=rifapentine; DOT=directly observed therapy; SAT=self-administered treatment; IQR=interquartile range: HIV = human immunodeficiency virus.